Media

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

Vicore Pharma Elects Peter Guenter to its Board of Directors

Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)

Vicore Pharma – Interim Report January – March 2026

Oncopeptides – Invitation to presentation of the Q1 report 2026

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference

Oncopeptides publishes the 2025 Annual Report

Intervacc brings together leading US and European experts to jointly tackle strangles